UK markets closed

Journey Medical Corporation (DERM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.4000-0.1000 (-2.86%)
At close: 04:00PM EDT

Journey Medical Corporation

9237 East Via de Ventura Boulevard
Suite 105
Scottsdale, AZ 85258
United States
480 434 6670
https://journeymedicalcorp.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees41

Key executives

NameTitlePayExercisedYear born
Dr. Lindsay Allan RosenwaldExecutive Chairman50kN/A1955
Mr. Claude MaraouiFounder, President, CEO & Director820.3kN/A1967
Mr. Joseph M. BeneschInterim CFO & Corporate ControllerN/AN/A1967
Mr. Andrew J. ZwibleVice President of OperationsN/AN/AN/A
Mr. Ramsey AlloushGeneral Counsel & Company SecretaryN/AN/A1986
Mr. Robert NevinChief Commercial OfficerN/AN/A1968
Jaclyn JaffeSenior Director of Corporate OperationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Corporate governance

Journey Medical Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.